If a prescription drug needs a hard sell, can it really be all that good?

A new analysis suggests the answer is no, at least in Canada.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • There is a reason why drug reps do not promote the drugs on the WHO EML. All of the meds on the list from what I can see are generic. With the typical pharma company paying $3000 or more a day for one rep to visit 10 docs it it doesn’t make sense for them to be pushing generics. One also might argue the definition of “essential”. For example there are no TNF inhibitors on the list for rheumatoid arthritis, just the ones I learned about when I took pharmacology 45 years ago.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy